Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Aldeyra Therapeutics (ALDX) Prices 5.25M Share Common Offering at $13.75/ShSeptember 28, 2018 5:34 AM Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $30 at Cantor FitzgeraldSeptember 26, 2018 9:33 AM Aldeyra Therapeutics (ALDX) Set to Up Higher by 60% Following Positive Results from Phase 2b Dry Eye Disease Clinical TrialSeptember 26, 2018 7:33 AM Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical TrialSeptember 26, 2018 7:00 AM